SecurityTCDA / Tricida, Inc.
Institutional Owners0

Institutional Stock Ownership and Shareholders()

Tricida, Inc. (NASDAQ:TCDA) has 0 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). Largest shareholders include .
Tricida, Inc. (NASDAQ:TCDA) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds more than 5% of the company and intends to actively pursue a change in business strategy. Schedule 13G indicates a passive investment of over 5%. Green rows indicate new positions. Red rows indicate closed positions. Click the link icon to see the full transaction history.

Important Note!
Note: We do not currently have a CUSIP on file for this security. That means we are unable to search institutional fund filings (13F's) for this company, which means there may be institutional holders that we are unaware of. If you know the CUSIP or would like us to research and update this security, please let us know by leaving a message in the Welcome Group.
File DateFormInvestor Opt Prev
Prev Value
Current Value

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

Related News Stories

Stocks To Watch: FANGs Out In Tech

2018-07-21 seekingalpha
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. (675-2)

Tricida IPO: Almost Completed Phase 3 And A Massive Total Addressable Market

2018-07-08 seekingalpha
Tricida is trying to sell 10.3 million shares at $16-18 per share, which will trade on the Nasdaq under the symbol TCDA. (10-1)

Rounds Report: Endocyte Rallied While The Tricida IPO Was A Success

2018-07-06 seekingalpha
The overall bioscience market enjoyed a strong trading day. Many equities under our coverage continued to log further gains for shareholders. (3-3)

IPO News This Week: Market Takes A Holiday After Record Week

2018-07-01 247wallst
Last week’s initial public offering (IPO) calendar included 13 firms looking to enter the public markets. All but one were successful and raised a total of around $2.3 billion in new capital, about $500 million less than planned. The coming week with its July 4 holiday falling on Wednesday has no IPOs scheduled. (6-0)

U.S. IPO Weekly Recap: 12 IPOs Price In Record-Setting Week, Month And Quarter

2018-06-30 seekingalpha
June 2018 also set a record as the most active month for IPOs in three years. And as IPO Pro subscribers can see in our newly-released Second Quarter IPO Review: the 2Q18 saw more IPOs than any quarter in three years, driven by a flood of biotechs and high-flying tech deals. Year-to-date, IPO proceeds and deal flow are about 40% higher than this point last year. Coming up, the IPO pipeline is prepped for another big quarter, starting with more biotechs. (89-3)